Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: An immunohistochemical study

British Journal of Dermatology

Volumn 150, Issue 5, 2004, Pages 940-948

  Simonetti, O ^a   Lucarini, G ^a   Bernardini, M L ^a   Simoncini, C ^a   Biagini, G ^a   Offidani, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Alopecia areata; CCL27; Diphencyprone; p16; Survivin; Vascular endothelial growth factor

Indexed keywords

CHEMOKINE; CHEMOKINE CCL27; DIPHENCYPRONE; PROTEIN P16; SURVIVIN; UNCLASSIFIED DRUG; VASCULOTROPIN; BETA CHEMOKINE; BIRC5 PROTEIN, HUMAN; BLOOD CLOTTING FACTOR 8; CCL27 PROTEIN, HUMAN; CTAGE1 PROTEIN, HUMAN; CYCLOPROPANE DERIVATIVE; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN P16INK4A; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; ALOPECIA AREATA; ANTIGEN EXPRESSION; ARTICLE; CELL COUNT; CELL LABELING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HAIR CELL; HAIR FOLLICLE; HAIR ROOT; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MALE; MICROSCOPY; MICROVASCULATURE; PRIORITY JOURNAL; SCALP; SKIN BIOPSY; T LYMPHOCYTE; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; ENZYME IMMUNOASSAY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ALOPECIA AREATA; ANTIGENS, NEOPLASM; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLOPROPANES; FACTOR VIII; FEMALE; HAIR FOLLICLE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE GLYCOPROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 3042823930     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.05881.x     Document Type: Article

References (50)

1. Messenger AG, Bleehen SS. Expression of HLA by anagen hair follicles in alopecia areata. J Invest Dermatol 1978; 85: 569-72.
2. Bodemer C, Peuchmauer M, Fraitaig S et al. Role of cytotoxic T cells in chronic alopecia areata. J Invest Dermatol 2000; 114: 112-16.
3. Randall VA. Is alopecia areata an autoimmune disease? Lancet 2001; 358: 1922-3.
4. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001; 107: 409-17.
5. Otomo S. Hair growth effect of minoxidil. Nippon Yakurigaku Zasshi 2002; 119: 167-74.
6. Dvorak HF, Brown LF, Detmar M, Dvorak A. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
7. Ferrara N, Houk K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 1992; 13: 18-32.
8. Goldman CK, Tsai JC, Roroceanu L, Gillespie Y. Loss of vascular endothelial growth factor in human alopecia areata hair follicles. J Invest Dermatol 1995; 104 (Suppl.): 18-20S.
9. Meckleunburg L, Tobin DJ, Muller-Rover S et al. Active hair growth (anagen) is associated with angiogenesis. J Invest Dermatol 2000; 114: 909-16.
10. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13: 239-52.
11. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7: 542-7.
12. O'Connor DS, Schechner JS, Adida C et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156: 393-8.
13. Karsan A, Harlan JM. Modulation of endothelial cell apoptosis: mechanism and pathophysiological roles. J Atheroscler Thromb 1996; 3: 75-80.
14. Pavey S, Russell T, Gabrielli B. G2 phase cell cycle arrest in human skin following UV irradiation. Oncogene 2001; 20: 6103-10.
15. Perret C, Weisner Menzel L, Happle R. Immunohistochemical analysis of T cell subsets in the peribulbal and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol (Stockh) 1984; 64: 26-30.
16. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans. Am J Pathol 1990; 136: 1053-68.
17. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration lymphocytes. Immunity 2002; 16: 1-4.
18. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001; 137: 1063-8.
19. Hoffmann R, Wenzel E, Huth A et al. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 1994; 103: 530-3.
20. Happle R, Hausen BM, Wiesner Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol (Stockh) 1983; 63: 49-52.
21. Detmar M, Yeo KT, Nagy JA et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995; 105: 44-50.
22. Kozlowska U, Blume-Peytavi U, Kodelja V et al. Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res 1998; 290: 661-8.
23. Weninger W, Uthman A, Pammer J et al. Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumours. Lab Invest 1996; 75: 647-57.
24. Madami S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42: 549-66.
25. Stenn MD, Fernadez LA, Tirell SJ. The angiogenic properties of the rat vibrissae hair follicle associate with the bulb. J Invest Dermatol 1988; 90: 409-11.
26. Frank S, Hubner G, Breier G et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 1995; 270: 12607-13.
27. Lachgar S, Charvéron M, Gall Y et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138: 407-11.
28. Cher DJ, Mosmann TR. Two types of murine helper T cell clones. II. Delayed-type hypersensitivity is mediated by Th1 clones. J Immunol 1987; 138: 3688-94.
29. Enk AH, Katz S. Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci USA 1992; 89: 1398-402.
30. Lisby S, Müller KM, Jongeneel V et al. Nickel and skin irritants up-regulate tumor necrosis factor-α mRNA in keratinocytes by different but potentially synergistic mechanisms. Int Immunol 1995; 7: 343-52.
31. Sebastiani S, Albanesi C, De Pità O et al. The role of cytokines in allergic contact dermatitis. Arch Dermatol Res 2002; 293: 552-9.
32. Mesri M, Morales-Ruiz M, Ackermann EJ et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001; 158: 1757-65.
33. Spadafora FM, Lopez AA, Coelho V et al. Two novel anti-von Willebrand factor monoclonal antibodies. Thromb Res 2000; 97: 3-13.
34. Weedon D, Strutton G. The recognition of early stages of catagen. Am J Dermatopathol 1984; 6: 553-5.
35. O'Reilly LA, Strasser A. Apoptosis and autoimmunity disease. Inflamm Res 1999; 48: 5-21.
36. Chiodino C, Cesinaro AM, Ottani D et al. Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 1999; 113: 415-18.
37. Offidani A, Lucarini G, Cellini A et al. Immunohistochemical localization of TGF-β in the skin of patients with alopecia areata. J Eur Acad Dermatol Venereol 1996; 7: 75-7.
38. Chaturvedi V, Qin J-Z, Denning MF et al. Apoptosis in proliferating, senescent and immortalized keratinocytes. J Biol Chem 1999; 274: 23358-67.
39. Gilhar A, Landau M, Assy B et al. Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice. Arch Dermatol 2002; 138: 916-22.
40. Ranki A, Kianto U, Kanerva L et al. Immunohistochemical and electron microscopic characterization of the cellular infiltrate in alopecia (areata, totalis and universalis). J Invest Dermatol 1984; 83: 7-11.
41. Christoph T, Muller-Rover S, Audring H et al. The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol 2000; 142: 862-73.
42. Happle R, Klein HM, Macher E. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 1986; 278: 214-18.
43. Thein C, Strange P, Hansen ER, Baadsgaard O. Lesional alopecia areata T lymphocytes downregulate epithelial cell proliferation. Arch Dermatol Res 1997; 289: 384-8.
44. Mosmann TR, Schumacher JH, Fiorentino DF et al. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6 and a new Th2 specific cytokine (IL-10, cytokine synthesis inhibitory factor) by using a solid-phase radioimmunoadsorbent assay. J Immunol 1990; 145: 2938-45.
45. de Waal Malefyt R, Abrams J, Bennet B et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-20.
46. Kalish RS, Gilhar A. The immunology of alopecia areata and potential application to novel therapy. Dermatol Ther 2001; 14: 322-8.
47. Morales J, Homey B, Vicari AP et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 1999; 96: 14470-5.
48. Homey B, Alenius H, Müller A et al. CCL-27-CCR10 interactions regulate T cell-mediated skin inflammation. Nature Med 2002; 8: 157-65.
49. Nibbs RJB, Graham GJ. CCL27/PESKY. a novel paradigm for chemokine funtion. Exp Opin Biol Ther 2003; 3: 15-22.
50. Reiss Y, Proudfoot AE, Power CA et al. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001; 194: 1541-7.